The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
June 26th 2025
Primary and secondary end points were demonstrated in a phase 3 trial of subcutaneous marstacimab as treatment for patients with hemophilia A or B.
Pediatric Patients With ASMD Show Significant Improvement in Olipudase Alfa Trial
December 4th 2021Findings from the single-arm, open-label ASCEND-Peds trial suggest olipudase alfa is well-tolerated and may lead to clinically meaningful improvements in patients with acid sphingomyelinase deficiency (ASMD) who do not have neurovisceral manifestations.
Read More
Genomic Profiling Identifies 3 NSCLC Subtypes Predictive of Adjuvant Therapy Outcomes
December 2nd 2021Next-generation sequencing uncovered 3 subtypes of epidermal growth factor receptor–mutant stage 2 and 3 non–small cell lung cancer (NSCLC) that predicted patient outcomes to adjuvant therapy.
Read More
Rituximab Infusion Timing, Dosing and COVID-19 Hospitalization Not Linked, Study Says
December 1st 2021A study examining the relation between rituximab infusion and hospitalization as a result of COVID-19 for patients with multiple sclerosis (MS) found that the 2 were not related, contradicting past research.
Read More
NGS, Prediction Tools Show Similarities Between Metastatic Breast Cancer, Other Advanced Cancers
November 27th 2021Next-generation sequencing (NGS) and the use of prediction tools in 2 patients with a rare form of metastatic breast cancer revealed mutations in malignant phyllodes tumors that are often detected in other advanced cancers, providing insight into potential therapeutic targets for these patients.
Read More
George Van Antwerp: Specialty Drugs Rely on Personalization for Optimal Outcomes
November 24th 2021The high cost of specialty drugs makes it important to use companion diagnostics and other tests to make sure the drug is going to the right patient, said George Van Antwerp, MBA, managing director, Deloitte Consulting.
Watch
Researchers Identify Novel Biomarker, Therapeutic Target for Polycythemia Vera
November 24th 2021The data set included 177 samples from polycythemia vera, essential thrombocytopenia, primary myelofibrosis, and healthy donors, from which the researchers found that MAPK14 was overexpressed in PV samples and was associated with more symptoms and worse outcomes.
Read More
Machine Learning Approach Finds Several Severity-Associated Factors in Atopic Dermatitis
November 23rd 2021Findings of a machine learning-based deep phenotyping approach found a myriad of factors associated with severe disease in atopic dermatitis, including age between 12 and 21 years or older than 52 years, lack of physical activity, and incidence of alopecia areata.
Read More
Study Finds Link Between Ultrasounds, PROs in Patients With RA, Low Disease Activity
November 23rd 2021New research found that residual inflammation in ultrasound images was associated with patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) with low disease activity, but not in patients in remission.
Read More
Dr Robert Hopkin on Emerging Therapeutic, Technological Advancements in Fabry Disease
November 19th 2021Robert J. Hopkin, MD, clinical geneticist, Cincinnati Children's Hospital Medical Center, discusses current and emerging therapeutic and technological advancements in the management of Fabry disease.
Watch
Bariatric Surgery Reduced Risk of Major Adverse Liver, CV Outcomes in Patients With NASH
November 18th 2021Patients with nonalcoholic steatohepatitis (NASH) and obesity had a reduced risk of major adverse liver outcomes and major adverse cardiovascular (CV) events after they underwent bariatric surgery compared with patients who did not have surgery.
Read More
Researchers Report Promising Strategy to Develop Personalized Therapy for Neuroblastoma
November 18th 2021Using cell cultures from pediatric patients with neuroblastoma, researchers performed drug-response testing and investigated correlations between copy number and cytotoxicity of drug treatment.
Read More
Sacubitril/Valsartan Treatment for HFpEF Shown to Reduce NT-proBNP Levels
November 18th 2021Wanting more data on the benefits of sacubitril/valsartan vs renin angiotensin system inhibitor background therapy, investigators conducted a large randomized study among persons with heart failure with preserved ejection fraction (HFpEF).
Read More
HRQOL Decreased During and Immediately After CAR T-Cell Therapy for DLBCL
November 16th 2021Prior to chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), patients experienced a decrease in health-related quality of life (HRQOL), which was further impaired during and immediately after CAR T therapy.
Read More